BMS nabs hep c partner Zymogenetics for $885M; Sun prevails in Taro's court challenge;

@FiercePharma: Weldon: J&J's recall probe almost wrapped. Article | Follow @FiercePharma

> Bristol-Myers Squibb agreed to acquire ZymoGenetics, the maker of a hepatitis C drug the companies were jointly developing, for $885 million. News

> India's Sun Pharmaceutical Industries took a big leap towards taking control of Israel's Taro Pharmaceutical Industries. Report

> Use of biomarkers in clinical trials to grow at blistering pace. News

> Allergan directors should be held liable for opening up the maker of wrinkle smoother Botox to criminal sanctions and a $600 million settlement by allowing the drug to be marketed for unapproved uses, investors said in a lawsuit. Article

> Biomarker helps guide study on smoking cessation treatments. Report

> Researchers' biomarker discovery could help those with Alzheimer's. Item

> Standard & Poor's Ratings Services may cut its credit ratings on Sanofi-Aventis, which is trying to buy the biotechnology company Genzyme. Article

> Merck's antipsychotic drug Saphris won the FDA nod for two additional uses: ongoing schizophrenia treatment and as an add-on to bipolar standbys lithium and valproate. Item

> Purdue Pharma has agreed to pay $16 million to settle a lawsuit by purchasers of Oxycontin over how it obtained patents on the painkiller in the 1990s. Story

> Lonza said it would manufacture a number of drug compounds for GlaxoSmithKline, adding to signs of a revival in demand from pharmaceutical clients. Report

> More than 80 percent of U.K. pharmacists say it is now more difficult than ever to obtain branded medicines and many expect things to get worse next year, a new survey shows. News

Biotech News

 @FierceBiotech: Actavis eyes fast-growing biosimilar market. News | Follow @FierceBiotech

 @JohnCFierce:  Biovail, Valeant plan to cut 25% of combined staffs. Get the impression from Reuters that R&D is getting downplayed. Article | Follow @JohnCFierce

> Zogenix files for $90 million IPO. Report

> Third Rock pushes Rhythm venture round to $40 million. News

> Onyx snags $339 million Japan deal for PhIII cancer med. Article

Medical Device News

> St. Jude invests $60M in CardioMEMS. Report

> Garrett resigns as Beckman Coulter CEO. News

> Sicel names McDaniel interim president, avoids bankruptcy. Item

> Invacare asks ITC to exclude beds. Story

Drug Delivery News

> FDA OKs thin-film version of opioid-dependence drug. Report

> BDSI, Meda, FDA talk about streamlining REMS for Onsolis. Story

> SHL says "Good Golly" to "Molly" in syringe marketing campaign. Article

> Alexza licenses Staccato nicotine delvery to Cypress Bioscience. Item

And Finally... Israeli scientists found a significant link between taking cholesterol-lowering statin drugs like Pfizer's Lipitor or AstraZeneca's Crestor and a reduced risk of developing rheumatoid arthritis. Article

Suggested Articles

J&J's talc woes deepened Friday after the FDA turned up "sub-trace" levels of asbestos one bottle of the company's baby powder,…

Another major drugmaker is recalling in the U.K. 10 batches of its Zantac generics because they contain a possible carcinogen.

With diagnosis rates on the rise, Pfizer's Vyndaqel franchise could collect $157 million in 2019 U.S. sales, well above consensus, SVB Leerink says.